Call us directly: +44 (0)7905 201857

Email us

Members log in


SEHTA is a not-for-profit company advised by a high-profile Board of industry representatives

The Board consists of:

Nick Rodgers – Chairman

Nick is an experienced non executive director and chairman with a background as a successful corporate financier. Significant exposure to companies in the healthcare, medical, biotechnology and environmental sectors.

He is the chief executive and founder of Ipso Ventures plc, a creator and investor in early stage technology and healthcare businesses.  Nick is also chairman of Oxford BioMedica plc, a leading gene based biopharmaceutical company.

Prior to founding IPSO in 2005 Nick was an investment banker and joint head of corporate finance with Evolution Securities (formerly Beeson Gregory). Has advised on over 100 acquisitions or disposals, some 40 flotations and in excess of 20 takeovers.

Nick is also a non executive director of oncology drug developer Morvus Technology and bio ethanol developer TMO Renewables.

Dr David Parry – CEO

David Parry was appointed Chief Executive of SEHTA on February 1st 2006. Immediately prior to this he ran his own life sciences consultancy company and was a SEEDA enterprise hub director for 3 years when he actively helped 20 small technology-based businesses to grow. Davids’ earlier background was in research and development. He has held positions of Head of Entomology and Plant Pathology at East Malling Research Station and Reader in Plant Pathology at Harper Adams University College. David has a track record in attracting funding from commercial, government and EU sources. His research work is widely published and he has written 2 books. David is a graduate of Imperial College and obtained his PhD from Imperial College at Wye.

Robert Berry

Rob Berry

Rob Berry is the Head of Innovation and Research in KSS AHSN and has responsibility for developing and implementing activities to support better engagement and collaboration between industry and the health system.  Rob has a predominantly NHS acute sector, teaching hospital background with significant leadership and business experience. He has supported improvement activities across a wide range of clinical (medical and surgical), clinical support (therapeutic and diagnostic) and system support services (including estates, IT and procurement). More recently he has managed competitive processes for technology development through the Small Business Research Initiatives (SBRI) and is currently a Board member of the Healthcare SBRI.

Rob has complemented his practical experience with academic studies recently completing his Masters in Health Care Management. His wider understanding of health economics including market failure has been used to inform the development of KSS AHSN market access services locally. Nationally Rob supported the development of the Academic Health Science Network policy has chaired the national AHSN Commercial Directors’ Forum and is a member of the AHSN Network’s Medicines Optimisation group as well as the NICE Implementation Collaborative a national cross sector group.  He is also a Board member of South East Health Technologies Alliance.

Dr Des Holden

Des was appointed as a consultant in Obstetrics and Gynaecology at Royal Sussex County Hospital in 2000 after a role at St George’s Hospital Des HoldenMedical School where he was the Lecturer in Fetal Medicine.  He became an Honorary Clinical Senior Lecturer at the Brighton and Sussex Medical School in 2003.

Des has held various managerial posts at BSUH and was appointed Medical Director there in 2009.

Since 2011 he has held the post for Medical Director at Surrey and Sussex Healthcare and was appointed as the Clinical Director of the Regional Enhancing Quality Programme, reducing variations in the management of several common clinical diagnoses within and between acute providers across all acute trusts in Kent, Surrey and Sussex.  Des was appointed as Medical Director of the KSS AHSN in 2014.  He is a regional expert and advisor to APEC, the national charity supporting action against pre-eclampsia.

Martyn Buxton-Hoare

After studying medicine, Martyn worked in pharmaceutical industry sales and sales management before joining the Wellcome Foundation (now GSK) and moving to Cairo where he ran the medical team and laid the foundations for the new veterinary business.  He then sMartynBuxtonHoare picturepent extensive periods for the Wellcome Foundation in Iraq and Syria as Country Manager before taking positions as a Group Marketing Manager for Zovirax and Group IP Licensing Manager.

He moved to Japan in a senior marketing role in Nippon Wellcome and later became President of a Japanese Pearson Group subsidiary in Marketing Services before moving back to the UK as Managing Director of Keeler, an ophthalmic medical device company.  He subsequently headed the surgical business for Advanced Medical Optics (now Abbott Medical Optics) in UK/Ireland.

In the University sector Martyn was Commercial Director of a Hull University spin-out responsible for commercial contracts, the IP portfolio and pilot manufacture, and transfer of technology to China and he was previously Director Technology Transfer at the University of Surrey, where he helped create impact in society and the economy from the university’s research by creating working partnerships, forming companies and licensing technology.  He has recently retired from the University of Surrey.

Professor James Moore

Jimmy received his Bachelor of Mechanical Engineering, his Master of Science in Mechanical Engineering and his Ph.D., all from the Georgia Institute of Technology. He had postdoctoral trainingJimmy More at the Swiss Institute of Technology at Lausanne. He has served as a Professor of Mechanical and Biomedical Engineering, Florida International University. He moved to Texas A&M University in 2003, Director of Graduate Studies. In January 2013, he joined Imperial College as the Bagrit and Royal Academy of Engineering Chair in Medical Device Design.

His research interests include Cardiovascular Biomechanics, Implantable Devices, Atherosclerosis, and the Lymphatic System. His research focuses on the role of biomechanics in the formation and treatment of diseases such as atherosclerosis and cancer. His cardiovascular biomechanics research includes the first studies of the effects of combined flow and stretch on vascular endothelium, and the first studies of the effects of stents on both blood flow patterns and artery wall stress. This work resulted in the development of two novel stent designs aimed at optimizing post-implant biomechanics for the prevention of restenosis.  His research on lymphatic system biomechanics has provided unprecedented insight into the pumping characteristics of the system and the transport of nitric oxide, antigens, and chemokines. He is currently developing two technologies for preventing and resolving secondary lymphedema, which typically forms subsequent to cancer surgery. Along with his funding from government, charity, and industry sources, he has received multiple patents for medical devices and testing equipment.  Jimmy has also co-founded two start-up companies.

Dr David Tuch

David is the Founder and CEO of Lightpoint Medical. He has more than a decade of David Tuchexperience in the medical imaging and pharmaceutical sectors. Previously, he was Head of Research Alliances at GE Healthcare and Head of Clinical Imaging at Novartis. Before joining industry, Dr. Tuch served on the faculty of Harvard Medical School and Massachusetts General Hospital, Department of Radiology. Dr. Tuch holds a PhD from MIT and Harvard Medical School, a BA from the University of Chicago, and has completed executive education at INSEAD.


George SampsonGeorge Sampson

George Sampson has greater than 35 years’ experience in the Medical products segment of Healthcare. The majority of this has been in Corporations such as American Hospital Supply, Baxter Healthcare, Dräger and Stryker. He has also participated in the construction of commercial organizations in newer ventures – The Urotech Division of Biocompatibles International, Tissuemed, SIRTeX Medical and as CEO of Parafricta.

He currently has his own consultancy, Quintain Medical Ltd., working with medical technology companies and innovation organisations. In addition, he was on the Selection Panel for the NIHR i4i Product Development grant awards for 6 years.


SEHTA Enterprises, founded in July 2011,  is the commercial arm of SEHTA

It’s board consists of:

Nick Rodgers

Dr David Parry